On Apr. 26, 2021, Moderna announced that it had entered into an agreement with Sanofi for fill/finish sterile manufacturing services and supply packaging for up to 200 million doses of the Moderna COVID-19 Vaccine in the U.S. beginning in September 2021. Sanofi leveraged its established manufacturing infrastructure at its site in Ridgefield, NJ.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.

To date, 24 development programs were underway across these therapeutic areas, with 13 programs having entered the clinic. Moderna was named a top biopharmaceutical employer by Science for the past six years.